---

---

publishing date : 2022 - 02 - 15    tags : Therapeutics   

save search

---

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
NKTX | $7.26 -6.8% -7.3% 730K |

Health Technology

| -27.1% | O: 1.9% H: 4.42% C: 2.94%
CRSP M | $55.04 -1.99% -2.03% 1.8M |

Health Technology

| -6.07% | O: 2.37% H: 2.27% C: 1.62%
financial results therapeutics crispr report results

---

U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
MRTX | $58.7 -0.17% 0.34% 0 |

Health Technology

| -42.03% | O: 1.42% H: 5.52% C: 4.35%
krasg12 new drug treatment fda application drug therapeutics cel food lung cancer cancer fda acceptance

---

Renibus Therapeutics Announces Appointment of Frank Stonebanks as CEO and $35 Million Series A Funding
Published: 2022-02-15 (Crawled : 18:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -10.68% | O: 0.32% H: 1.19% C: 0.71%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -11.39% | O: 1.0% H: 0.99% C: 0.47%
ces ceo therapeutics funding one

---

Horizon Therapeutics plc Partners with the Doug the Pug Foundation and Sing Me A Story Foundation to Bring Awareness to Rare Diseases Impacting Children through #RAREis Playlist
Published: 2022-02-15 (Crawled : 18:00) - biospace.com/
HZNP | $116.3 0.03% 29M |

Health Technology

| 20.53% | O: 1.72% H: 1.0% C: 0.02%
rare therapeutics disease children

---

Avenue Therapeutics Stock Trading Halted TodayFDA Advisory Committee to review IV tramadol New Drug Application
Published: 2022-02-15 (Crawled : 15:30) - biospace.com/
ATXI | $0.1295 -3.79% -3.94% 320K |

Health Technology

| Email alert Add to watchlist
new drug day fda application drug therapeutics oda

---

Axsome Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
Published: 2022-02-15 (Crawled : 15:00) - biospace.com/
AXSM | $67.91 3.33% 3.22% 890K |

Health Technology

| 117.63% | O: 2.12% H: 6.65% C: 5.93%
financial results therapeutics report results

---

Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
Published: 2022-02-15 (Crawled : 14:30) - biospace.com/
NTLA | $21.57 1.17% 1.16% 1.4M |

Health Technology

| -76.12% | O: 2.09% H: 8.24% C: 6.85%
treatment therapeutics crispr cel intel collaboration cancer

---

Data from Qualigen Therapeutics’ Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 Conference
Published: 2022-02-15 (Crawled : 14:30) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K |

Health Technology

| -55.98% | O: 0.41% H: 4.51% C: 0.75%
qn-302 program conference therapeutics presentation

---

Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
Published: 2022-02-15 (Crawled : 14:00) - biospace.com/
JAGX | $0.158 -10.79% -12.09% 30M |

Health Technology

| -74.07% | O: 3.73% H: 3.75% C: 2.34%
health europe therapeutics designation

---

Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
BCLI A | $0.5384 4.69% 4.48% 1M |

Health Technology

| -82.51% | O: -0.33% H: 5.3% C: 3.31%
nurown patent therapeutics cel brazil grant granted

---

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M |

Health Technology

| 38.08% | O: 2.51% H: 8.21% C: 6.84%
america multiple sclerosis treatment als trials research trial therapeutics presentation sclerosis phase 3

---

Last Patient Completes Treatment in Stealth BioTherapeutics' Phase 2 Geographic Atrophy Clinical Trial
Published: 2022-02-15 (Crawled : 13:30) - biospace.com/
MITO | $0.32 0.25% |

Health Technology

| -48.88% | O: 0.64% H: 11.11% C: 3.16%
treatment phase 2 trial therapeutics iot

---

Grey Wolf Therapeutics Announces Formation of Clinical Advisory Board in Anticipation of Advancing First-in-Class Immuno-Oncology Approach into the Clinic
Published: 2022-02-15 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 209.48% | O: 0.84% H: 3.44% C: 3.04%
ces therapeutics

---

Avenue Therapeutics Stock Trading Halted Today
Published: 2022-02-15 (Crawled : 12:30) - globenewswire.com
ATXI | $0.1295 -3.79% -3.94% 320K |

Health Technology

| Email alert Add to watchlist
day therapeutics oda

---

Cerevel Therapeutics Announces Positive Topline Results for Darigabat in Phase 1 Clinical Trial in Acute Anxiety
Published: 2022-02-15 (Crawled : 12:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K |

Finance

| 35.72% | O: -3.25% H: 2.19% C: 0.03%
trial therapeutics phase 1 topline results positive topline phase 2 phase 3

---

Gainers vs Losers

67%

33%

Top 10 Gainers

---

Your saved searches

---